ECSP109910A - DERIVATIVES OF N- (ARILAMINO) SULFONAMIDS THAT INCLUDE POLYMORPHES AS INHIBITORS OF MEK AS WELL AS COMPOSITIONS, METHODS OF USE AND PREPARATION OF THE SAME - Google Patents

DERIVATIVES OF N- (ARILAMINO) SULFONAMIDS THAT INCLUDE POLYMORPHES AS INHIBITORS OF MEK AS WELL AS COMPOSITIONS, METHODS OF USE AND PREPARATION OF THE SAME

Info

Publication number
ECSP109910A
ECSP109910A EC2010009910A ECSP109910A ECSP109910A EC SP109910 A ECSP109910 A EC SP109910A EC 2010009910 A EC2010009910 A EC 2010009910A EC SP109910 A ECSP109910 A EC SP109910A EC SP109910 A ECSP109910 A EC SP109910A
Authority
EC
Ecuador
Prior art keywords
compositions
methods
compounds
mek
arilamino
Prior art date
Application number
EC2010009910A
Other languages
Spanish (es)
Inventor
Jean-Luc Girardet
Jean-Michel Vernier
Colin Edward Rowlings
Stuart Dimock
Barry Quart
Jeffrey N Miner
Original Assignee
Ardea Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40304796&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP109910(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/830,733 external-priority patent/US8101799B2/en
Application filed by Ardea Biosciences Inc filed Critical Ardea Biosciences Inc
Publication of ECSP109910A publication Critical patent/ECSP109910A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/28—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N41/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom
    • A01N41/02—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a sulfur atom bound to a hetero atom containing a sulfur-to-oxygen double bond
    • A01N41/04—Sulfonic acids; Derivatives thereof
    • A01N41/06—Sulfonic acid amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Plant Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Rheumatology (AREA)
  • Dentistry (AREA)

Abstract

Esta invención se relaciona con compuestos N-(2-arilamino) aril sulfonamida que son inhibidores de MEK incluyendo formas polimórficas cristalinas que exhiben un perfil de difracción de rayos X en polvo específico y/o un perfil de calorimetría diferencial de barrido específico. Esta invención también se relaciona con composiciones farmacéuticas que comprenden los compuestos descritos y métodos de uso de los compuestos y composiciones descritos, incluyendo el uso en el tratamiento y/o prevención de cáncer, enfermedades hiperproliferativas y condiciones inflamatorias. La invención también se relaciona con métodos para obtener los compuestos y composiciones que se describen.This invention relates to N- (2-arylamino) aryl sulfonamide compounds that are MEK inhibitors including crystalline polymorphic forms exhibiting a specific powder X-ray diffraction profile and / or a specific scanning differential calorimetry profile. This invention also relates to pharmaceutical compositions comprising the described compounds and methods of use of the described compounds and compositions, including use in the treatment and / or prevention of cancer, hyperproliferative diseases and inflammatory conditions. The invention also relates to methods for obtaining the compounds and compositions described.

EC2010009910A 2007-07-30 2010-01-29 DERIVATIVES OF N- (ARILAMINO) SULFONAMIDS THAT INCLUDE POLYMORPHES AS INHIBITORS OF MEK AS WELL AS COMPOSITIONS, METHODS OF USE AND PREPARATION OF THE SAME ECSP109910A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/830,733 US8101799B2 (en) 2005-07-21 2007-07-30 Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
US3446408P 2008-03-06 2008-03-06
US3446608P 2008-03-06 2008-03-06
US4488608P 2008-04-14 2008-04-14

Publications (1)

Publication Number Publication Date
ECSP109910A true ECSP109910A (en) 2010-04-30

Family

ID=40304796

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2010009910A ECSP109910A (en) 2007-07-30 2010-01-29 DERIVATIVES OF N- (ARILAMINO) SULFONAMIDS THAT INCLUDE POLYMORPHES AS INHIBITORS OF MEK AS WELL AS COMPOSITIONS, METHODS OF USE AND PREPARATION OF THE SAME

Country Status (22)

Country Link
EP (1) EP2184984A4 (en)
JP (3) JP2010535232A (en)
KR (3) KR20150091434A (en)
CN (2) CN103479604B (en)
AP (1) AP2817A (en)
AU (2) AU2008282338B2 (en)
BR (1) BRPI0815659A2 (en)
CA (1) CA2693390C (en)
CO (1) CO6470808A2 (en)
CR (1) CR11244A (en)
DO (1) DOP2010000045A (en)
EA (2) EA032294B1 (en)
EC (1) ECSP109910A (en)
HN (1) HN2010000203A (en)
IL (1) IL203296A (en)
MA (1) MA31881B1 (en)
MX (1) MX2010001244A (en)
NZ (1) NZ582929A (en)
PH (1) PH12015501914A1 (en)
SV (1) SV2010003469A (en)
TN (1) TN2010000049A1 (en)
WO (1) WO2009018233A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
MX2010011314A (en) * 2008-04-14 2010-11-12 Ardea Biosciences Inc Compositions and methods for preparing and using same.
KR101822319B1 (en) * 2008-09-09 2018-01-25 에프. 호프만-라 로슈 아게 Polymorphs of acyl sulfonamides
SG190568A1 (en) 2008-09-26 2013-06-28 Oncomed Pharm Inc Frizzled-binding agents and uses thereof
UY32486A (en) * 2009-03-11 2010-10-29 Ardea Biosciences Inc TREATMENT OF CANCER CANCER
WO2010105110A1 (en) 2009-03-11 2010-09-16 Ardea Biosciences, Inc. Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers
CN102666512B (en) 2009-10-13 2014-11-26 奥斯特姆医疗公司 Novel MEK inhibitors, useful in the treatment of diseases
EP2491015A1 (en) * 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
TWI535445B (en) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt antagonists and methods of treatment and screening
CN102020651B (en) 2010-11-02 2012-07-18 北京赛林泰医药技术有限公司 6-aryl amino pyridone formamide MEK (methyl ethyl ketone) inhibitor
CN102649773A (en) * 2011-02-23 2012-08-29 苏州波锐生物医药科技有限公司 Amino aromatic hydrocarbon compound and application thereof to preparation of medicine for resisting malignant tumor
BR112013027448A2 (en) * 2011-04-28 2020-09-01 Sloan-Kettering Institute For Cancer Research combination therapy with hsp90
AU2012264884B2 (en) * 2011-05-27 2017-03-09 Bayer Intellectual Property Gmbh Chiral synthesis of N-{3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]-6-methoxyphenyl}-1-[2,3-dihydroxy-propyl]cyclopropanesulfonamides
EP2788378A4 (en) * 2011-12-09 2015-09-09 Oncomed Pharm Inc ASSOCIATION THERAPY FOR THE TREATMENT OF CANCER
WO2013109142A1 (en) 2012-01-16 2013-07-25 Stichting Het Nederlands Kanker Instituut Combined pdk and mapk/erk pathway inhibition in neoplasia
JP2015527874A (en) * 2012-05-31 2015-09-24 バイエル ファーマ アクチエンゲゼルシャフト Biomarkers for determining an effective response to treatment of hepatocellular carcinoma (HCC) patients
KR20210033067A (en) 2012-06-04 2021-03-25 파마싸이클릭스 엘엘씨 Crystalline forms of a bruton's tyrosine kinase inhibitor
FI3702351T3 (en) * 2012-10-19 2024-01-24 Array Biopharma Inc Formulation comprising a mek inhibitor
US20150265679A1 (en) 2012-11-02 2015-09-24 The United States Of America, As Represented By Secretary, Department Of Health And Human Services Method of reducing adverse effects in a cancer patient undregoing treatment with a mek inhibitor
AU2014212081A1 (en) 2013-02-04 2015-08-13 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a Wnt pathway inhibitor
EP2848246A1 (en) 2013-09-13 2015-03-18 Bayer Pharma Aktiengesellschaft Pharmaceutical compositions containing refametinib
WO2015041534A1 (en) 2013-09-20 2015-03-26 Stichting Het Nederlands Kanker Instituut P90rsk in combination with raf/erk/mek
US9629851B2 (en) 2013-09-20 2017-04-25 Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis ROCK in combination with MAPK pathway
WO2015156674A2 (en) 2014-04-10 2015-10-15 Stichting Het Nederlands Kanker Instituut Method for treating cancer
WO2015178770A1 (en) 2014-05-19 2015-11-26 Stichting Het Nederlands Kanker Instituut Compositions for cancer treatment
US20170114323A1 (en) 2014-06-19 2017-04-27 Whitehead Institute For Biomedical Research Uses of kinase inhibitors for inducing and maintaining pluripotency
EP3185900A4 (en) 2014-08-25 2018-05-02 Aimmune Therapeutics, Inc. Egg protein formulations and methods of manufacture thereof
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of proton tyrosine kinase inhibitor
TW201904577A (en) * 2017-06-16 2019-02-01 美商貝達醫藥公司 N-(2-(2-Dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl Pharmaceutical formulation of amino)phenyl) acrylamide and its salts
EA202192575A1 (en) 2019-03-21 2022-01-14 Онксео DBAIT COMPOUNDS IN COMBINATION WITH KINASE INHIBITORS FOR CANCER TREATMENT
JP2022551439A (en) * 2019-10-04 2022-12-09 スミトモ ファーマ オンコロジー， インコーポレイテッド AXL inhibitor formulation
CN114761006A (en) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) Methods of treating cancer resistant to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
US12371667B2 (en) 2021-05-13 2025-07-29 Washington University Enhanced methods for inducing and maintaining naive human pluripotent stem cells
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma
CN118834328B (en) * 2024-07-02 2025-09-16 江苏海洋大学 Preparation method and application of metalloprotease 9 epitope imprinting nano-particles

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162117A (en) * 1991-11-22 1992-11-10 Schering Corporation Controlled release flutamide composition
JP2575590B2 (en) * 1992-07-31 1997-01-29 塩野義製薬株式会社 Triazolylthiomethylthiocephalosporin hydrochloride and its hydrate crystals and their preparation
ES2123065T3 (en) * 1992-08-25 1999-01-01 Searle & Co HYDROXYETHYLAMINE-SULFONAMIDES USEFUL AS RETROVIRAL PROTEASE INHIBITORS.
US7115632B1 (en) * 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
DE69926914T2 (en) * 1999-01-13 2006-06-29 Warner-Lambert Co. Llc 1-HETEROCYCLE SUBSTITUTED DIARYLAMINES
GB0003224D0 (en) * 2000-02-11 2000-04-05 Glaxo Group Ltd Chemical compounds
US7235567B2 (en) * 2000-06-15 2007-06-26 Schering Corporation Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist
EP1429713A4 (en) * 2001-09-24 2007-08-08 Jessie L S Au Methods and compositions to determine the chemosensitizing dose of suramin used in combination therapy
AU2003251942A1 (en) * 2002-07-17 2004-02-02 Titan Pharmaceuticals, Inc. Combination of chemotherapeutic drugs for increasing antitumor activity
JP2005535688A (en) * 2002-07-30 2005-11-24 ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング Use of alkylphosphocholines in combination with antitumor drugs
AU2006235487B2 (en) * 2005-04-12 2011-12-22 Elan Pharma International Limited Nanoparticulate quinazoline derivative formulations
WO2006115154A1 (en) * 2005-04-22 2006-11-02 Kissei Pharmaceutical Co., Ltd. Crystal polymorphism of 4’-{2-[(1s,2r)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethylamino]ethoxy}-3-isopropyl-3’,5’-dimethylbiphenylcarboxylic acid hydrochloride
CA2618218C (en) * 2005-07-21 2015-06-30 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
JP2007099763A (en) * 2005-09-08 2007-04-19 Toyama Chem Co Ltd Novel crystals of piperacillin sodium monohydrate and process for producing the same
TW200800150A (en) * 2005-12-21 2008-01-01 Organon Nv Compounds with medicinal effects due to interaction with the glucocorticoid receptor

Also Published As

Publication number Publication date
JP2015078199A (en) 2015-04-23
EA201400552A1 (en) 2014-09-30
PH12015501914A1 (en) 2017-07-31
TN2010000049A1 (en) 2011-09-26
EA201000268A1 (en) 2010-08-30
NZ582929A (en) 2012-03-30
CN103479604A (en) 2014-01-01
CN103479604B (en) 2016-08-10
CN101808516A (en) 2010-08-18
AP2817A (en) 2013-12-31
SV2010003469A (en) 2010-04-30
JP6309880B2 (en) 2018-04-11
KR20150091434A (en) 2015-08-10
CO6470808A2 (en) 2012-06-29
CA2693390A1 (en) 2009-02-05
AU2008282338A1 (en) 2009-02-05
DOP2010000045A (en) 2010-10-31
MA31881B1 (en) 2010-12-01
IL203296A (en) 2017-06-29
AU2015200390B2 (en) 2017-02-23
BRPI0815659A2 (en) 2014-09-30
MX2010001244A (en) 2010-08-31
JP2010535232A (en) 2010-11-18
AU2008282338B2 (en) 2015-02-12
EP2184984A1 (en) 2010-05-19
CR11244A (en) 2010-05-20
JP2017125021A (en) 2017-07-20
HN2010000203A (en) 2012-11-19
WO2009018233A1 (en) 2009-02-05
HK1147396A1 (en) 2011-08-12
EA020624B1 (en) 2014-12-30
KR20140098185A (en) 2014-08-07
EA032294B1 (en) 2019-05-31
AP2010005134A0 (en) 2010-02-28
KR20100092424A (en) 2010-08-20
CN101808516B (en) 2013-08-28
CA2693390C (en) 2017-01-17
EP2184984A4 (en) 2013-07-24

Similar Documents

Publication Publication Date Title
ECSP109910A (en) DERIVATIVES OF N- (ARILAMINO) SULFONAMIDS THAT INCLUDE POLYMORPHES AS INHIBITORS OF MEK AS WELL AS COMPOSITIONS, METHODS OF USE AND PREPARATION OF THE SAME
CY1121195T1 (en) TETRAHYDRONAPHTALENE DERIVATIVES INHIBITING MCL-1 PROTEIN
UY31254A1 (en) SUBSTITUTED DERIVATIVES OF N4- (5-METHYL-1H-PIRAZOL-3-IL) - 1,3,5-TRIAZINA-2,4-DIAMINE, THEIR ENANTIOMERS, PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME, COMPOSITIONS, PREPARATION PROCESSES AND APPLICATIONS
DOP2016000271A (en) FUSIONED BICYCLIC HETEROARILO OR ARILO COMPOUNDS
UY31481A1 (en) NEW PIRIMIDINE DERIVATIVES, PREPARATION PROCESSES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND APPLICATIONS
CL2015002635A1 (en) Compounds and compositions for the treatment of parasitic diseases
CO6620050A2 (en) Aminopyrimidine derivatives as modulators of lrrk2
ECSP088749A (en) TETRAHYDROPIRIDOTIENOPIRIMIDINE COMPOUNDS AND PROCEDURES FOR THE SAME USE
ECSP077268A (en) RAPAMYCIN POLYMORPH II AND THE USES OF THE SAME
UY29781A1 (en) DIAZASPIRO SUBSTITUTE COMPOUNDS, PHARMACEUTICALLY ACCEPTABLE SALTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THE COMPOUNDS OR SALTS, PREPARATION METHODS AND USES
UA99731C2 (en) CRYSTAL POLYMORPH FORMS OF N- (ARLYMINO) SULPHONAMIDES AS MECHANISM INHIBITORS, COMPOSITION (OPTIONS) AND APPLICATIONS
EA201390908A1 (en) DERIVATIVES OF BICYCLO [3.2.1] OCTYLAMIDE AND THEIR APPLICATION
UY33921A (en) N-SUBSTITUTED OXAZINOPTERIDINS AND N-REPLACED OXAZINOPTIRIDINONES
CU20110235A7 (en) IMIDAZOLIDIN-2-ONA 1,3-DISPOSED DERIVATIVES AS CYP17 INHIBITORS
BR112012013431A2 (en) compound, pharmaceutical composition and its use
CO6321282A2 (en) PIPERIDINYLINDOL DERIVATIVES AS INHIBITORS OF ALDOSTERONA SINTASA
UY29795A1 (en) ADENINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCESSES AND APPLICATIONS
UA114944C2 (en) PRIDINYLINE AND CONDENSED PRIDYNYLINE TRIASOLONE DERIVATIVES
UY31885A (en) DERIVED FROM THE 1, 3, 5-TRIAZINA-2, 4-DIAMINAS-6-SUBSTITUTED-N-SUBSTITUTED AND PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME, COMPOSITIONS AND APPLICATIONS.
UY35275A (en) AMINOPIRAZINE DERIVATIVES
MX2019012847A (en) C5-anilinoquinazoline compounds and their use in treating cancer.
CO2020004977A2 (en) Bicyclic compounds for use as ripi kinase inhibitors
CY1123880T1 (en) INNOVATIVE 5-HT2 COMPETITORS
DOP2006000061A (en) PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
CO6321280A2 (en) NEW ESPIRO PIPERIDINAS CLASS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES